We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NSPR Stock Declines Despite PMA Application Submission for CGuard
Read MoreHide Full Article
InspireMD (NSPR - Free Report) recently announced that it has submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval for the CGuard Prime carotid stent system in the United States.
NSPR’s quest for U.S. approval of its next-generation CGuard Prime stent, which offers best-in-class clinical outcomes to treat carotid artery disease and stroke prevention, has advanced significantly with the submission of the PMA application to the FDA.
Upon successful marketing approval of the CGuard Prime carotid stent system in the United States, the company is likely to launch the product in the first half of 2025 commercially. The stent system is expected to contribute significantly to boosting the top-line growth of the company.
However, shares of NSPR have lost 2.23% in the pre-market session on Sept. 17.
More on NSPR’s PMA Application
The PMA application is based on the overwhelmingly positive one-year data from the company’s C-GUARDIANS pivotal clinical trial that was presented at the Leipzig Interventional Course (LINC) 2024 in May. The C-GUARDIANS clinical trial evaluated the safety and efficacy of CGuard for the treatment of carotid artery stenosis. The study enrolled 316 patients across 24 trial sites in the United States and Europe.
The C-GUARDIANS results showed a primary endpoint major adverse event rate of 1.95% through 12 months post-procedure, the lowest such event rate reported for any carotid stent or embolic protection device pivotal trial to date.
More on NSPR’s CGuard EPS & Recent Developments
The CGuard Embolic Prevention Carotid Stent System (EPS) is a novel mesh carotid stent designed to improve patient safety by offering continuous embolic support. By trapping potential emboli against the arterial wall, CGuard EPS preserves external carotid artery perfusion and avoids late and peri-procedural embolization.
In May, NSPR presented the C-GUARDIANS U.S. pivotal trial positive study data. On the second-quarter earnings call, management commented that it expects to commence enrollment in C-GUARDIANS II in the back half of 2024. The company anticipates FDA approval of the company’s C-Guard stent for integration with SILK’s neuroprotection system in the second half of 2025. Additionally, NSPR continues to expect approval for its SwitchGuard TCAR system in the first half of 2026.
Favorable Industry Prospects for NSPR
Per a report by Grand View Research, the carotid artery stents market size was estimated to be $559.7 million in 2021 and is projected to witness a CAGR of 3% during the 2022-2030 period.
Given the market potential, NSPR’s CGuard Prime carotid stent system is likely to provide a boost to the company’s business.
Price Performance of NSPR Stock
In the past six months, NSPR’s shares have gained 18.4% compared with the industry’s 2.2% rise. The S&P 500 has increased 9.3% in the same time frame.
Image Source: Zacks Investment Research
NSPR’s Zacks Rank & Stocks to Consider
NSPR carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are Universal Health Service (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and ABM Industries (ABM - Free Report) . While Universal Health Service currently sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
The company has gained 41.1% so far this year compared with the industry's 34.8% growth.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.
The company’s shares have gained 3.7% so far this year compared with the industry’s 10.2% growth.
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NSPR Stock Declines Despite PMA Application Submission for CGuard
InspireMD (NSPR - Free Report) recently announced that it has submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval for the CGuard Prime carotid stent system in the United States.
NSPR’s quest for U.S. approval of its next-generation CGuard Prime stent, which offers best-in-class clinical outcomes to treat carotid artery disease and stroke prevention, has advanced significantly with the submission of the PMA application to the FDA.
Upon successful marketing approval of the CGuard Prime carotid stent system in the United States, the company is likely to launch the product in the first half of 2025 commercially. The stent system is expected to contribute significantly to boosting the top-line growth of the company.
However, shares of NSPR have lost 2.23% in the pre-market session on Sept. 17.
More on NSPR’s PMA Application
The PMA application is based on the overwhelmingly positive one-year data from the company’s C-GUARDIANS pivotal clinical trial that was presented at the Leipzig Interventional Course (LINC) 2024 in May. The C-GUARDIANS clinical trial evaluated the safety and efficacy of CGuard for the treatment of carotid artery stenosis. The study enrolled 316 patients across 24 trial sites in the United States and Europe.
The C-GUARDIANS results showed a primary endpoint major adverse event rate of 1.95% through 12 months post-procedure, the lowest such event rate reported for any carotid stent or embolic protection device pivotal trial to date.
More on NSPR’s CGuard EPS & Recent Developments
The CGuard Embolic Prevention Carotid Stent System (EPS) is a novel mesh carotid stent designed to improve patient safety by offering continuous embolic support. By trapping potential emboli against the arterial wall, CGuard EPS preserves external carotid artery perfusion and avoids late and peri-procedural embolization.
In May, NSPR presented the C-GUARDIANS U.S. pivotal trial positive study data. On the second-quarter earnings call, management commented that it expects to commence enrollment in C-GUARDIANS II in the back half of 2024. The company anticipates FDA approval of the company’s C-Guard stent for integration with SILK’s neuroprotection system in the second half of 2025. Additionally, NSPR continues to expect approval for its SwitchGuard TCAR system in the first half of 2026.
Favorable Industry Prospects for NSPR
Per a report by Grand View Research, the carotid artery stents market size was estimated to be $559.7 million in 2021 and is projected to witness a CAGR of 3% during the 2022-2030 period.
Given the market potential, NSPR’s CGuard Prime carotid stent system is likely to provide a boost to the company’s business.
Price Performance of NSPR Stock
In the past six months, NSPR’s shares have gained 18.4% compared with the industry’s 2.2% rise. The S&P 500 has increased 9.3% in the same time frame.
Image Source: Zacks Investment Research
NSPR’s Zacks Rank & Stocks to Consider
NSPR carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are Universal Health Service (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and ABM Industries (ABM - Free Report) . While Universal Health Service currently sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
The company has gained 41.1% so far this year compared with the industry's 34.8% growth.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.
The company’s shares have gained 3.7% so far this year compared with the industry’s 10.2% growth.
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% growth.